Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how? [0.03%]
临床观点：克罗恩病的血清和预后生物标志物：谁、何时以及如何？
Marla C Dubinsky
Marla C Dubinsky
The introduction of anti-tumor necrosis factor-a therapies has significantly expanded the armamentarium for patients with inflammatory bowel disease (IBD). Clinical experience has shown that not all patients respond to therapies in this cla...
Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments [0.03%]
克罗恩病的临床展望。运用抗TNF-α治疗向前迈进：目前的需求和未来的疗法
William J Sandborn
William J Sandborn
Although infliximab continues to make an important contribution to the management of Crohn's disease, its use includes several clinical challenges, including loss of response, loss of tolerability due to acute and delayed infusion reactions...
Clinical perspectives in Crohn's disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down" [0.03%]
克罗恩病的临床展望。“传统治疗策略的新思维：目前“逐渐升级方案”与“全面启动方案”的证据分析
Stephen B Hanauer
Stephen B Hanauer
The current Crohn's disease treatment algorithm involves a "step-up" approach in which conventional medications such as corticosteroids are given first and anti-tumor necrosis factor-a (TNF-a) agents are reserved for refractory cases. Altho...
Clinical perspectives in Crohn's disease: now and in the future. Introduction [0.03%]
克罗恩病的临床展望：现在与未来。前言
William J Sandborn
William J Sandborn
Uma Mahadevan
Uma Mahadevan
Medical options for Crohn's disease are expanding at an unprecedented rate. The anti-tumor necrosis factor-a (TNF-a) agents infliximab, adalimumab, and certolizumab pegol have proven efficacy for induction and maintenance of remission among...
Refining the role of TNF antagonists for Crohn's disease. Introduction [0.03%]
抗TNF药物在克罗恩病治疗中的作用再认识——序论
Stephen B Hanauer,William J Sandborn
Stephen B Hanauer
Edward V Loftus Jr
Edward V Loftus Jr
It is expected that within a few months, there will be commercially available in the United States a total of 3 biologic agents with inhibition of tumor necrosis factor-a (TNF-a) as the primary mechanism of action: infliximab, adalimumab, a...
Crohn's disease in patients who fail infliximab therapy: what does the future hold? [0.03%]
英夫利昔治疗失败的克罗恩病患者：未来如何？
Maria T Abreu
Maria T Abreu
Patients who respond to infliximab enjoy many benefits, including improvement in clinical symptoms, less disability, and a better quality of life. Unfortunately, many patients are unresponsive to infliximab therapy. They may be completely r...
Danial E Baker
Danial E Baker
Natalizumab is a humanized monoclonal antibody that is produced in murine myeloma cells. It functions in the body as an antagonist of integrin heterodimers that contain the a4 integrin subunit. These heterodimers include a4b1 integrin and a...
Endoscopic ultrasound and percutaneous access for endoscopic biliary and pancreatic drainage after initially failed ERCP [0.03%]
内镜超声和经皮穿刺途径在内镜逆行胰胆管造影失败后的胆胰管引流中的应用
Kapil Gupta,Shawn Mallery,David Hunter et al.
Kapil Gupta et al.
Although the success rates of endoscopic retrograde cholangiopancreatography (ERCP) in accessing the bile and pancreatic ducts are quite high, failure to achieve duct access still occurs. Options in these cases have traditionally included p...